Oligomeric compounds for the modulation of HIF-1alpha expression
First Claim
1. A method of treating a mammal suffering from cancer, comprising administering to the mammal a therapeutically effective amount of an oligonucleotide compound targeted to Hif-1alpha and having the base sequence set forth in SEQ ID NO:
- 55, wherein the cancer is selected from the group consisting of kidney cancer, melanoma, glioblastoma and prostate cancer, and wherein the oligonucleotide compound comprises one or more LNA units.
4 Assignments
0 Petitions
Accused Products
Abstract
Oligonucleotides directed against the hypoxia-inducible factor-1α (HIP-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
-
Citations
9 Claims
-
1. A method of treating a mammal suffering from cancer, comprising administering to the mammal a therapeutically effective amount of an oligonucleotide compound targeted to Hif-1alpha and having the base sequence set forth in SEQ ID NO:
- 55, wherein the cancer is selected from the group consisting of kidney cancer, melanoma, glioblastoma and prostate cancer, and wherein the oligonucleotide compound comprises one or more LNA units.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
Specification